/ Glenmark gets tentative ANDA Approval For Saxagliptin Tablets ~ Ways2Capital|Stock Tips|Stock Market Tips|Intraday Stock Tips|Stock Trading Tips|NSE BSE Tips

Wednesday, 14 June 2017

Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted tentative approval by the United States Food & Drug Administration (US FDA) for Saxagliptin Tablets, 2.5 mg and 5 mg. It is the generic version of Onglyza® Tablets, 2.5 mg and 5 mg of AstraZeneca AB, according to a BSE filing.

The stock is trading at Rs 632.95 per share, up by 0.3% at 1047 hours IST on BSE. It touched a high of Rs 635.05 and a low of Rs 628 so far during the day.

Glenmark Pharmaceuticals has underperformed BSE mid-cap and BSE Healthcare over a period of one year. Its peers are Alkem Laboratories and Torrent Pharmaceuticals.

Glenmark Pharmaceuticals Limited is a global pharmaceutical company. It is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs).

or Quick Trial – 8962000225 ✔ 
or mail us here: info@ways2capital.com
or visit http://www.ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007 ✔ 
Give a Missed Call for Free Trial - 09699997717 ✔